(GKOS) Glaukos - Ratings and Ratios
Micro-stents, Intraocular Drug Implants, Ophthalmic Surgical Tools
GKOS EPS (Earnings per Share)
GKOS Revenue
Description: GKOS Glaukos
Glaukos Corporation is a medical technology company that specializes in developing innovative therapies for treating various eye disorders, including glaucoma, corneal disorders, and retinal diseases. The companys product portfolio includes a range of micro-invasive surgical devices and pharmaceutical therapies, such as iStent and iDose TR, designed to restore natural outflow pathways and reduce intraocular pressure.
From a business perspective, Glaukos has a diversified revenue stream, selling its products to ambulatory surgery centers, hospitals, and physician private practices through a combination of direct sales and distribution channels. The companys global presence is supported by its headquarters in Aliso Viejo, California, and its international reach.
To evaluate Glaukos performance, key performance indicators (KPIs) such as revenue growth, gross margin, and research and development (R&D) expenditure as a percentage of revenue can be considered. For instance, a high R&D expenditure as a percentage of revenue may indicate the companys commitment to innovation and potential for future growth. Additionally, metrics like customer acquisition cost and customer retention rate can provide insights into the companys sales and marketing effectiveness.
From a financial perspective, Glaukos market capitalization is approximately $6.2 billion, indicating a significant presence in the healthcare equipment industry. The companys return on equity (ROE) is currently negative, suggesting that it may be investing heavily in its growth initiatives. To further assess the companys financial health, metrics like debt-to-equity ratio, interest coverage ratio, and cash flow from operations can be analyzed.
In terms of growth prospects, Glaukos pipeline products, such as iLink and ILution, may offer opportunities for expansion into new therapeutic areas. The companys retinal XR platform also has potential for treating various posterior segment retinal diseases. By analyzing the companys product development pipeline and upcoming milestones, investors can gauge the potential for future revenue growth.
GKOS Stock Overview
| Market Cap in USD | 5,019m |
| Sub-Industry | Health Care Equipment |
| IPO / Inception | 2015-06-25 |
GKOS Stock Ratings
| Growth Rating | 5.17% |
| Fundamental | 32.8% |
| Dividend Rating | - |
| Return 12m vs S&P 500 | -45.0% |
| Analyst Rating | 4.27 of 5 |
GKOS Dividends
Currently no dividends paidGKOS Growth Ratios
| Growth Correlation 3m | -73.7% |
| Growth Correlation 12m | -72.9% |
| Growth Correlation 5y | 61.2% |
| CAGR 5y | 12.92% |
| CAGR/Max DD 3y | 0.26 |
| CAGR/Mean DD 3y | 1.82 |
| Sharpe Ratio 12m | -0.47 |
| Alpha | -54.08 |
| Beta | 0.919 |
| Volatility | 43.42% |
| Current Volume | 794k |
| Average Volume 20d | 666.5k |
| Stop Loss | 79.3 (-4.2%) |
| Signal | -1.31 |
Piotroski VR‑10 (Strict, 0-10) 0.5
| Net Income (-92.8m TTM) > 0 and > 6% of Revenue (6% = 26.0m TTM) |
| FCFTA -0.07 (>2.0%) and ΔFCFTA 1.63pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue 82.44% (prev 91.80%; Δ -9.36pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA -0.02 (>3.0%) and CFO -20.6m > Net Income -92.8m (YES >=105%, WARN >=100%) |
| NO Net Debt/EBITDA fails (EBITDA <= 0) |
| Current Ratio 5.51 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (56.9m) change vs 12m ago 12.24% (target <= -2.0% for YES) |
| Gross Margin 76.34% (prev 76.53%; Δ -0.19pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 45.42% (prev 37.16%; Δ 8.26pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio -16.60 (EBITDA TTM -62.2m / Interest Expense TTM 5.55m) >= 6 (WARN >= 3) |
Altman Z'' -4.56
| (A) 0.36 = (Total Current Assets 436.1m - Total Current Liabilities 79.1m) / Total Assets 987.0m |
| (B) -0.79 = Retained Earnings (Balance) -783.2m / Total Assets 987.0m |
| (C) -0.10 = EBIT TTM -92.1m / Avg Total Assets 953.3m |
| (D) -3.52 = Book Value of Equity -780.3m / Total Liabilities 221.8m |
| Total Rating: -4.56 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 32.84
| 1. Piotroski 0.50pt = -4.50 |
| 2. FCF Yield -1.36% = -0.68 |
| 3. FCF Margin -15.62% = -5.86 |
| 4. Debt/Equity 0.29 = 2.46 |
| 5. Debt/Ebitda -3.57 = -2.50 |
| 6. ROIC - WACC -21.22% = -12.50 |
| 7. RoE -12.52% = -2.09 |
| 8. Rev. Trend 97.34% = 4.87 |
| 9. Rev. CAGR 22.35% = 2.50 |
| 10. EPS Trend 45.64% = 1.14 |
| 11. EPS CAGR 0.0% = 0.0 |
What is the price of GKOS shares?
Over the past week, the price has changed by -11.90%, over one month by -7.37%, over three months by -15.20% and over the past year by -34.46%.
Is Glaukos a good stock to buy?
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of GKOS is around 69.03 USD . This means that GKOS is currently overvalued and has a potential downside of -16.59%.
Is GKOS a buy, sell or hold?
- Strong Buy: 9
- Buy: 3
- Hold: 2
- Sell: 0
- Strong Sell: 1
What are the forecasts/targets for the GKOS price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 122.5 | 48% |
| Analysts Target Price | 122.5 | 48% |
| ValueRay Target Price | 77.3 | -6.6% |
Last update: 2025-09-12 04:37
GKOS Fundamental Data Overview
CCE Cash And Equivalents = 274.8m USD (Cash And Short Term Investments, last quarter)
P/E Forward = 1666.6667
P/S = 11.5931
P/B = 6.5602
P/EG = 1.64
Beta = 0.77
Revenue TTM = 433.0m USD
EBIT TTM = -92.1m USD
EBITDA TTM = -62.2m USD
Long Term Debt = 142.7m USD (from nonCurrentLiabilitiesTotal, last quarter)
Short Term Debt = 79.1m USD (from totalCurrentLiabilities, last quarter)
Debt = 221.8m USD (Calculated: Short Term 79.1m + Long Term 142.7m)
Net Debt = 4.21m USD (from netDebt column, last quarter)
Enterprise Value = 4.97b USD (5.02b + Debt 221.8m - CCE 274.8m)
Interest Coverage Ratio = -16.60 (Ebit TTM -92.1m / Interest Expense TTM 5.55m)
FCF Yield = -1.36% (FCF TTM -67.6m / Enterprise Value 4.97b)
FCF Margin = -15.62% (FCF TTM -67.6m / Revenue TTM 433.0m)
Net Margin = -21.43% (Net Income TTM -92.8m / Revenue TTM 433.0m)
Gross Margin = 76.34% ((Revenue TTM 433.0m - Cost of Revenue TTM 102.4m) / Revenue TTM)
Tobins Q-Ratio = -6.36 (set to none) (Enterprise Value 4.97b / Book Value Of Equity -780.3m)
Interest Expense / Debt = 0.52% (Interest Expense 1.15m / Debt 221.8m)
Taxrate = 21.0% (US default)
NOPAT = -92.1m (EBIT -92.1m, no tax applied on loss)
Current Ratio = 5.51 (Total Current Assets 436.1m / Total Current Liabilities 79.1m)
Debt / Equity = 0.29 (Debt 221.8m / last Quarter total Stockholder Equity 765.1m)
Debt / EBITDA = -3.57 (Net Debt 4.21m / EBITDA -62.2m)
Debt / FCF = -3.28 (Debt 221.8m / FCF TTM -67.6m)
Total Stockholder Equity = 741.1m (last 4 quarters mean)
RoA = -9.40% (Net Income -92.8m, Total Assets 987.0m )
RoE = -12.52% (Net Income TTM -92.8m / Total Stockholder Equity 741.1m)
RoCE = -10.42% (Ebit -92.1m / (Equity 741.1m + L.T.Debt 142.7m))
RoIC = -12.20% (NOPAT -92.1m / Invested Capital 755.3m)
WACC = 9.02% (E(5.02b)/V(5.24b) * Re(9.40%)) + (D(221.8m)/V(5.24b) * Rd(0.52%) * (1-Tc(0.21)))
Shares Correlation 3-Years: 100.00 | Cagr: 1.64%
Discount Rate = 9.40% (= CAPM, Blume Beta Adj.)
Fair Price DCF = unknown (Cash Flow -67.6m)
Revenue Correlation: 97.34 | Revenue CAGR: 22.35%
Rev Growth-of-Growth: 8.96
EPS Correlation: 45.64 | EPS CAGR: 0.0%
EPS Growth-of-Growth: 68.02
Additional Sources for GKOS Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle